Quick Answer
RECURSION PHARMACEUTICALS, INC. reported Diluted EPS of $1.44 per share (loss) for fiscal year 2025.
RECURSION PHARMACEUTICALS, INC. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.44 | +14.8% |
| 2024 | -$1.69 | -7.0% |
| 2023 | -$1.58 | -16.2% |
| 2022 | -$1.36 | +8.7% |
| 2021 | -$1.49 | +62.7% |
| 2020 | -$3.99 | -39.0% |
| 2019 | -$2.87 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.36 | -5.9% | +12.2% |
| June 30, 2025 | -$0.41 | -2.5% | +18.0% |
| March 31, 2025 | -$0.50 | -28.2% | -47.1% |
| September 30, 2024 | -$0.34 | +20.9% | +15.0% |
| June 30, 2024 | -$0.40 | -5.3% | -2.6% |
| March 31, 2024 | -$0.39 | -14.7% | +9.3% |
| September 30, 2023 | -$0.43 | -22.9% | -13.2% |
| June 30, 2023 | -$0.38 | +0.0% | -11.8% |
- RECURSION PHARMACEUTICALS, INC. showed an increase of +14.8% in Diluted EPS compared to the prior fiscal year.
- Over the 2019–2025 period, RECURSION PHARMACEUTICALS, INC.’s diluted eps has grown by 49.8% (from $2.87 per share (loss) to $1.44 per share (loss)).
- The most recent figure is from RECURSION PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: